Neurocrine Biosciences (NASDAQ:NBIX) and Allena Pharmaceuticals (NASDAQ:ALNA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.
This table compares Neurocrine Biosciences and Allena Pharmaceuticals’ net margins, return on equity and return on assets.
This is a breakdown of current recommendations for Neurocrine Biosciences and Allena Pharmaceuticals, as provided by MarketBeat.
Neurocrine Biosciences presently has a consensus price target of $125.75, suggesting a potential upside of 13.75%. Allena Pharmaceuticals has a consensus price target of $31.67, suggesting a potential upside of 305.46%. Given Allena Pharmaceuticals’ higher possible upside, analysts plainly believe Allena Pharmaceuticals is more favorable than Neurocrine Biosciences.
Valuation & Earnings
This table compares Neurocrine Biosciences and Allena Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
Allena Pharmaceuticals has lower revenue, but higher earnings than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Allena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
84.9% of Allena Pharmaceuticals shares are owned by institutional investors. 4.3% of Neurocrine Biosciences shares are owned by insiders. Comparatively, 36.7% of Allena Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Allena Pharmaceuticals beats Neurocrine Biosciences on 6 of the 11 factors compared between the two stocks.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-74788, which is in Phase II clinical trial that is used for the treatment of congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, dystonia, and other indications. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women's and men's health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson's disease. The company also has a research collaboration agreement with Jnana Therapeutics Inc. to discover novel small molecule therapeutics for multiple targets for central nervous system disorders. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.